Source link : https://www.newshealth.biz/health-news/dazukibart-shows-promise-in-treating-dermatomyositis/
TOPLINE: Treatment with dazukibart, a monoclonal antibody targeting interferon beta, yielded a rapid reduction in dermatomyositis disease activity in adults with skin-predominant and muscle-predominant dermatomyositis, with nearly all patients showing a clinically meaningful decrease at week 12. METHODOLOGY: Researchers conducted a randomized phase 2 trial to evaluate the efficacy and safety of dazukibart in adults […]
Author : News Health
Publish date : 2025-01-17 06:37:35
Copyright for syndicated content belongs to the linked Source.
inHealth